Pacific Biosciences Of California (PACB) Capital Expenditures (2010 - 2026)

Pacific Biosciences Of California's Capital Expenditures history runs 17 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 119.08% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $4.4 million (up 18.12% YoY), while the FY2025 annual figure was $2.7 million, down 56.14% from the prior year.
• Capital Expenditures was $3.0 million for Q1 2026 at Pacific Biosciences Of California, up from $861000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $4.9 million in Q4 2022 to a low of -$787000.0 in Q3 2024.
• Historically, Capital Expenditures has averaged $2.2 million across 5 years, with a median of $2.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures jumped 807.23% in 2022, then tumbled 194.82% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $4.9 million in 2022, then slumped by 58.73% to $2.0 million in 2023, then decreased by 20.11% to $1.6 million in 2024, then slumped by 46.75% to $861000.0 in 2025, then soared by 253.43% to $3.0 million in 2026.
• The last three Capital Expenditures figures came in at $3.0 million (Q1 2026), $861000.0 (Q4 2025), and -$86000.0 (Q3 2025), per Business Quant data.